证券代码：603883 证券简称：老百姓 公告编号：2025-044 老百姓大药房连锁股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日召开了第五届董事会第十次会议和第五届监事会第七次会议审议通过了《关于 回购注销剩余限制性股票的议案》。鉴于 2022 年限制性股票激励计划激励对象 中 32 人已离职及首次授予第三个解除限售期、预留授予第二个解除限售期公司 层面业绩不达标，公司决定回购注销 2022 年限制性股票激励计划剩余的限制性 股票合计 1,205,377 股。本次限制性股票回购总金额 14,889,399.25 元（含利息）， 回购所需资金均来源于公司自有资金。现将相关事项公告如下： 一、公司 2022 年限制性股票激励计划审批程序及实施情况 《关于公司<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于公 司<2022 年限制性股票激励计划实施考核管理办法>的议案》及《关于提请股东 大会授权董事会办理 2022 ...

Group 1 - The core viewpoint of the news is the implementation of the new regulations allowing individual businesses to directly transform into limited companies or partnerships, which aims to alleviate the challenges faced by individual businesses in terms of procurement, management resources, and attracting investment [1][2] - Beijing Anxutang Pharmacy became the first company to receive a business license for transforming from a sole proprietorship to a limited company under the new regulations, highlighting the practical benefits of the policy [1] - The new regulations, consisting of 40 articles, address the unique legal attributes and operational characteristics of individual businesses, providing a framework for their development and ensuring better rights protection [2] Group 2 - The rapid implementation of the reform policy is attributed to the pilot experience gained in Zhongguancun since 2010, which has now been expanded nationwide, allowing more individual businesses to avoid the cumbersome process of cancellation and re-registration [2] - The regulations include measures such as establishing contact points for individual business development, targeted support, and optimizing the transition process to enhance the quality of development for individual businesses [2]

Core Viewpoint - The article highlights the successful implementation of a new regulation allowing sole proprietorships to directly transition into limited liability companies without the need for cancellation and re-registration, exemplified by the case of Beijing Anxutang Pharmacy [1][3][5]. Group 1: Policy Implementation - On July 15, the first business license for a sole proprietorship transitioning to a limited liability company was issued in Beijing's Fangshan District [3]. - The new regulation, known as the "Individual Industrial and Commercial Household Registration Management Regulations," allows sole proprietorships to convert to companies or partnerships, addressing previous challenges of having to cancel and reapply [5]. - The policy was expedited due to prior pilot experiences in the Zhongguancun National Independent Innovation Demonstration Zone, which began in 2010 [5]. Group 2: Business Challenges and Solutions - Anxutang Pharmacy faced difficulties such as weak purchasing power, insufficient operational resources, and challenges in attracting external investment, prompting the need for transformation [3]. - The transition to a limited liability company is expected to enable the pharmacy to implement equity incentives, attract professional talent, and enhance capital influx [3]. - The new regulation aims to provide a seamless transition for businesses, allowing them to maintain their brand and operational history [5]. Group 3: Broader Impact and Future Prospects - The regulation consists of 40 articles that refine the registration management rules for individual businesses, focusing on their unique legal attributes and operational characteristics [5]. - Beijing has been proactive in supporting the development of individual businesses, having completed 51,700 registrations for the transition from individual to corporate forms [5].

Core Points - The company announced a cash dividend distribution of 0.08 yuan per share for the fiscal year 2024, approved at the shareholders' meeting on June 30, 2025 [2][4] - The total cash dividend to be distributed amounts to approximately 60.81 million yuan, based on a total share capital of 760,095,613 shares [4] - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the registration date [3] Distribution Plan - The cash dividends will be distributed through the clearing system of the China Securities Depository and Clearing Corporation Limited, with shareholders who have completed designated transactions able to receive their dividends on the payment date [5] - The distribution does not involve the issuance of bonus shares or capital increases [6] - Direct cash dividends will be issued to specific shareholders, including Lao Bai Xing Medical Group Co., Ltd., Zexing Investment Co., Ltd., and Chen Xiulan [9] Taxation Details - For individual shareholders and securities investment funds holding unrestricted circulating shares, no income tax will be withheld at the time of dividend distribution, with the actual cash dividend being 0.08 yuan per share [10] - Tax liabilities will be calculated based on the holding period of the shares, with different tax rates applicable: 20% for holdings of one month or less, 10% for holdings between one month and one year, and no tax for holdings over one year [10] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of 0.072 yuan per share [11]

Core Points - The employee stock ownership plan (ESOP) of Dazhenglin Pharmaceutical Group Co., Ltd. will expire on December 3, 2025 [1][2] - The ESOP was approved at the fourth extraordinary general meeting of shareholders in 2020 and has a duration of 36 months [1] - The board of directors has approved an extension of the ESOP for an additional 12 months, now set to expire on December 3, 2025 [2] Summary of Employee Stock Ownership Plan - The ESOP currently holds 6,572,239 shares, representing 0.58% of the company's total share capital [2] - The company has adhered to market trading rules and regulations during the ESOP period, ensuring no insider trading occurred [2] - Upon expiration of the ESOP, it will terminate automatically, and the management committee will handle the disposal of remaining rights in accordance with relevant regulations [2]